Alexion
News/ News/ Sales and Marketing
Alexion finally has a buyer – and it’s AstraZeneca with $39bn on the table
Chasing Janssen, Alexion and Caelum start phase 3 AL amyloidosis trial
Richard Staines
AL amyloidosis, Alexion, Caelum Biosciences, Rare diseases
0 Comment
News/ News/ Sales and Marketing
Roche takes on Alexion as FDA approves satralizumab in NMOSD
Richard Staines
Alexion, inflammatory diseases, neurology, NMOSD, Roche
0 Comment
Alexion trials rare disease drug Ultomiris in severe COVID-19 cases
Richard Staines
Alexion, coronavirus, COVID-19, Ultomiris
0 Comment
Roche trumpets data for Soliris rival in NMOSD after US, EU filings
Phil Taylor
Alexion, rare disease, Roche, satralizumab, Soliris
0 Comment
News/ News/ Sales and Marketing/ Top stories
Alexion stalks rare disease drug from Stealth with $30m opt-in deal
Phil Taylor
Alexion, licensing, rare disease, Stealth Therapeutics
0 Comment
News/ News/ R&D/ Top stories
UCB sets sights on rare diseases giant Alexion with Ra Pharma acquisition
Richard Staines
Alexion, Ra Pharma, Rare diseases, UCB
0 Comment
News/ News/ R&D/ Top stories
Roche preps filings for satralizumab in rare disease NMOSD
Phil Taylor
Alexion, rare disease, Roche, satralizumab, Soliris
0 Comment